Re: Todayís CC
I havenít seen this kind of firework in pps for quite sometime. It is not that all the other biotechs are participating. It is definitely related to continued growth in Onpattro sales.
Management anticipates TTR is going to be multi billion dollar market opportunity for Alnylam if they are successful to expand in wild type CM market. So I expect TTR will be a major value driver for midterm and longterm if management is correct in their guidance.
Analysts were focused on Onpattro and no one asked any questions regarding any other drugs in the pipeline except for Givosiran. So no wonder HBV or any other drugs were not discussed. We will have to wait until November to get any news on HBV or AAT02.